JP2023553930A - トレブルチニブの結晶形態、その製造方法、およびその使用 - Google Patents
トレブルチニブの結晶形態、その製造方法、およびその使用 Download PDFInfo
- Publication number
- JP2023553930A JP2023553930A JP2023535327A JP2023535327A JP2023553930A JP 2023553930 A JP2023553930 A JP 2023553930A JP 2023535327 A JP2023535327 A JP 2023535327A JP 2023535327 A JP2023535327 A JP 2023535327A JP 2023553930 A JP2023553930 A JP 2023553930A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- csi
- present disclosure
- form csi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Inorganic Compounds Of Heavy Metals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025234453A JP2026041905A (ja) | 2020-12-10 | 2025-12-05 | トレブルチニブの結晶形態、その製造方法、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011455573.5 | 2020-12-10 | ||
| CN202011455573 | 2020-12-10 | ||
| PCT/CN2021/132028 WO2022121670A1 (zh) | 2020-12-10 | 2021-11-22 | Tolebrutinib的晶型及其制备方法和用途 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025234453A Division JP2026041905A (ja) | 2020-12-10 | 2025-12-05 | トレブルチニブの結晶形態、その製造方法、およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023553930A true JP2023553930A (ja) | 2023-12-26 |
| JP2023553930A5 JP2023553930A5 (cg-RX-API-DMAC7.html) | 2024-11-29 |
Family
ID=81974189
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535327A Pending JP2023553930A (ja) | 2020-12-10 | 2021-11-22 | トレブルチニブの結晶形態、その製造方法、およびその使用 |
| JP2025234453A Pending JP2026041905A (ja) | 2020-12-10 | 2025-12-05 | トレブルチニブの結晶形態、その製造方法、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025234453A Pending JP2026041905A (ja) | 2020-12-10 | 2025-12-05 | トレブルチニブの結晶形態、その製造方法、およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12049463B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4261212A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023553930A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102872880B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN118434732A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021398051B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3201936A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2023008949A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303590A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006854A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022121670A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CN117295735B (zh) * | 2021-04-23 | 2026-05-12 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) * | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2023280132A1 (zh) * | 2021-07-06 | 2023-01-12 | 苏州晶云药物科技股份有限公司 | 氧代二氢咪唑并吡啶类化合物的晶型及其制备方法 |
| CA3241687A1 (en) * | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| US20250188076A1 (en) | 2022-03-09 | 2025-06-12 | Teva Pharmaceutical International Gmbh | Solid state forms of tolebrutinib and of tolebrutinib salts |
| WO2026050513A1 (en) | 2024-08-30 | 2026-03-05 | Principia Biopharma Inc. | Tolebrutinib for multiple sclerosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504277A (ja) * | 2012-11-09 | 2016-02-12 | ツーチュン ハウティエン ファーム カンパニー リミテッド | ピロロキノリンキノン二ナトリウム塩の結晶 |
| JP2016094368A (ja) * | 2014-11-14 | 2016-05-26 | 大日本住友製薬株式会社 | ベンズイミダゾール化合物の新規結晶、及びその製造方法 |
| CN105753863A (zh) * | 2015-09-11 | 2016-07-13 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3760984A (en) | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
| US3952741A (en) | 1975-01-09 | 1976-04-27 | Bend Research Inc. | Controlled release delivery system by an osmotic bursting mechanism |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| US20060045822A1 (en) | 2004-09-01 | 2006-03-02 | Board Of Regents, The University Of Texas System | Plasma polymerization for encapsulating particles |
| AU2005284835A1 (en) | 2004-09-14 | 2006-03-23 | Novartis Vaccines And Diagnostics Inc. | Imidazoquinoline compounds |
| CA2597587A1 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
| US8846697B2 (en) | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
| EP2529621B1 (en) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| TW200911803A (en) | 2007-07-16 | 2009-03-16 | Organon Nv | 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US8940725B2 (en) | 2010-05-31 | 2015-01-27 | Ono Pharmaceutical Co., Ltd. | Purinone derivative |
| AU2012255860C1 (en) | 2011-05-17 | 2015-12-10 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| MX2013013331A (es) | 2011-05-17 | 2014-10-17 | Principia Biopharma Inc | Derivados de azaindol como inhibidores de tirosina-cinasas. |
| US9073947B2 (en) | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| BR112014012727B1 (pt) | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| CN104487441B (zh) | 2012-06-18 | 2018-06-01 | 普林斯匹亚生物制药公司 | 有用于治疗癌症和自身免疫性疾病的可逆的共价吡咯并嘧啶或吡唑并嘧啶 |
| SMT201900344T1 (it) | 2012-09-10 | 2019-07-11 | Principia Biopharma Inc | Composti di pirazolopirimidina come inibitori di chinasi |
| KR20150084923A (ko) | 2012-11-15 | 2015-07-22 | 파마시클릭스, 인코포레이티드 | 키나제 억제제로서의 피롤로피리미딘 화합물 |
| US20140142099A1 (en) | 2012-11-20 | 2014-05-22 | Principia Biopharma Inc. | Purinone Derivatives as Tyrosine Kinase Inhibitors |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| ME03000B (me) | 2012-12-21 | 2018-10-20 | Plexxikon Inc | Jedinjenja i metode modulacije kinaze i povezane indikacije |
| SG11201605417QA (en) | 2014-02-03 | 2016-08-30 | Cadila Healthcare Ltd | Heterocyclic compounds |
| AP2016009261A0 (en) * | 2014-02-07 | 2016-06-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| CN107001362A (zh) | 2014-10-06 | 2017-08-01 | 默克专利有限公司 | 用作btk抑制剂的杂芳基化合物及其用途 |
| WO2016086358A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Hydroxymethyl piperidine orexin receptor antagonists |
| EP3912979B1 (en) * | 2015-06-03 | 2026-03-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US10358446B2 (en) | 2015-10-14 | 2019-07-23 | Zibo Biopolar Changsheng Pharmaceutical Co., Ltd. | Bruton's tyrosine kinase inhibitors |
| KR102780243B1 (ko) | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| US20210113568A1 (en) | 2018-04-27 | 2021-04-22 | Ono Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASE COMPRISING COMPOUND HAVING Btk INHIBITORY ACTIVITY AS ACTIVE INGREDIENT |
| CA3168146A1 (en) | 2020-01-20 | 2021-07-29 | Genzyme Corporation | Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms) |
| CN115867346B (zh) | 2020-06-02 | 2025-03-14 | Gb005股份有限公司 | 激酶抑制剂 |
| WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| CA3201936A1 (en) | 2020-12-10 | 2022-06-16 | Minhua Chen | Crystal form of tolebrutinib and preparation method thereof |
| IL303834A (en) | 2020-12-23 | 2023-08-01 | Genzyme Corp | 4-amino-3-(4-phenoxyphenyl)-1,3-dihydro-2H-imidazo[4,5-C]pyridin-2-one derivatives and their salts |
| CN117295735B (zh) | 2021-04-23 | 2026-05-12 | 杭州领业医药科技有限公司 | Tolebrutinib晶型、无定型及其制备方法和用途 |
| CN117412749A (zh) | 2021-05-21 | 2024-01-16 | 杭州领业医药科技有限公司 | Tolebrutinib盐及其晶型、其制备方法、其药物组合物和用途 |
| WO2022257845A1 (zh) | 2021-06-11 | 2022-12-15 | 苏州科睿思制药有限公司 | Tolebrutinib的晶型及其制备方法和用途 |
| IL310975A (en) | 2021-09-03 | 2024-04-01 | Novartis Ag | LOU064 for the treatment of multiple sclerosis |
| CA3241687A1 (en) | 2021-12-21 | 2023-06-29 | Tim Owens | Crystalline forms of (r)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1h-imidazo[4,5-c]pyridin-2(3h)-one and salts thereof |
| CN119212708A (zh) | 2022-05-13 | 2024-12-27 | 普林斯匹亚生物制药公司 | 用于髓鞘少突胶质细胞糖蛋白抗体疾病(mogad)的治疗性酪氨酸激酶抑制剂 |
| US20260022123A1 (en) | 2022-06-22 | 2026-01-22 | Principia Biopharma Inc. | Methods of Making Modified BTK Inhibitors |
| CA3260159A1 (en) | 2022-06-30 | 2024-01-04 | Principia Biopharma Inc. | Therapeutic Tyrosine Kinase Inhibitors for the Treatment of Multiple Sclerosis and Myasthenia Gravis |
-
2021
- 2021-11-22 CA CA3201936A patent/CA3201936A1/en active Pending
- 2021-11-22 KR KR1020237023108A patent/KR102872880B1/ko active Active
- 2021-11-22 JP JP2023535327A patent/JP2023553930A/ja active Pending
- 2021-11-22 EP EP21902377.7A patent/EP4261212A4/en active Pending
- 2021-11-22 IL IL303590A patent/IL303590A/en unknown
- 2021-11-22 MX MX2023006854A patent/MX2023006854A/es unknown
- 2021-11-22 CN CN202180083380.8A patent/CN118434732A/zh active Pending
- 2021-11-22 WO PCT/CN2021/132028 patent/WO2022121670A1/zh not_active Ceased
- 2021-11-22 AU AU2021398051A patent/AU2021398051B2/en active Active
-
2022
- 2022-08-10 US US17/818,846 patent/US12049463B2/en active Active
-
2023
- 2023-07-05 CO CONC2023/0008949A patent/CO2023008949A2/es unknown
-
2024
- 2024-05-28 US US18/676,250 patent/US20240391915A1/en active Pending
-
2025
- 2025-12-05 JP JP2025234453A patent/JP2026041905A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016504277A (ja) * | 2012-11-09 | 2016-02-12 | ツーチュン ハウティエン ファーム カンパニー リミテッド | ピロロキノリンキノン二ナトリウム塩の結晶 |
| JP2016094368A (ja) * | 2014-11-14 | 2016-05-26 | 大日本住友製薬株式会社 | ベンズイミダゾール化合物の新規結晶、及びその製造方法 |
| CN105753863A (zh) * | 2015-09-11 | 2016-07-13 | 东莞市真兴贝特医药技术有限公司 | 氧代二氢咪唑并吡啶类化合物及其应用 |
Non-Patent Citations (1)
| Title |
|---|
| 第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0005499487 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3201936A1 (en) | 2022-06-16 |
| US20240391915A1 (en) | 2024-11-28 |
| US12049463B2 (en) | 2024-07-30 |
| IL303590A (en) | 2023-08-01 |
| AU2021398051A9 (en) | 2024-10-17 |
| EP4261212A1 (en) | 2023-10-18 |
| AU2021398051A1 (en) | 2023-07-27 |
| KR102872880B1 (ko) | 2025-10-20 |
| MX2023006854A (es) | 2023-07-20 |
| CN118434732A (zh) | 2024-08-02 |
| US20220389011A1 (en) | 2022-12-08 |
| JP2026041905A (ja) | 2026-03-10 |
| AU2021398051B2 (en) | 2026-07-30 |
| KR20230118154A (ko) | 2023-08-10 |
| EP4261212A4 (en) | 2024-11-27 |
| CO2023008949A2 (es) | 2023-09-29 |
| WO2022121670A1 (zh) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026041905A (ja) | トレブルチニブの結晶形態、その製造方法、およびその使用 | |
| EP4353723A1 (en) | Crystal form of tolebrutinib, preparation method therefor and use thereof | |
| AU2017336889B2 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| AU2015237744A1 (en) | Ibrutinib solid forms and production process therefor | |
| JP2023532787A (ja) | 結晶形態のウパダシチニブ(upadacitinib)、その調製方法及びその使用 | |
| EP3272748A1 (en) | Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate | |
| JP2024056724A (ja) | ムスカリン性アセチルコリン受容体アゴニストの結晶性多形 | |
| US11306062B2 (en) | Forms of fedratinib dihydrochloride | |
| JP2025503642A (ja) | (s)-5-ベンジル-n-(5-メチル-4-オキソ-2,3,4,5-テトラヒドロピリド[3,2-b][1,4]オキサゼピン-3-イル)-4h-1,2,4-トリアゾール-3-カルボキサミドの結晶性形態 | |
| CA3130107A1 (en) | Co-crystal forms of selinexor | |
| HK40094757A (en) | Crystal form of tolebrutinib, preparation method therefor and use thereof | |
| US20260001883A1 (en) | 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof | |
| HK40111001A (en) | Crystal form of tolebrutinib, preparation method therefor and use thereof | |
| AU2021231396A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine | |
| NZ792812A (en) | Crystalline polymorphs of a muscarinic acetylcholine receptor agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241121 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241121 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20241121 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250107 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250528 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20250805 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250813 |